Welcome to our dedicated page for Macrogenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics stock.
MacroGenics, Inc. (Nasdaq: MGNX) is a biopharmaceutical company that publicly describes its focus as discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The MGNX news page on Stock Titan aggregates company-issued updates and third-party coverage so readers can follow how MacroGenics communicates progress across its oncology pipeline, technology platforms and collaborations.
In its press releases, MacroGenics highlights clinical developments for programs such as lorigerlimab, a bispecific PD‑1 × CTLA‑4 DART® molecule, and a portfolio of antibody-drug conjugates including MGC026, MGC028 and MGC030. News items also describe partnered programs like MGD024 with Gilead Sciences, ZYNYZ® (retifanlimab-dlwr) with Incyte and TZIELD® (teplizumab-mzwv) associated with Sanofi, including milestone structures and royalty arrangements disclosed by the company.
MacroGenics regularly issues announcements on quarterly financial results, cash runway expectations, royalty purchase agreements and other financing-related transactions. Additional news covers participation in healthcare and investment conferences, leadership changes such as the appointment of a new President and Chief Executive Officer, and updates on strategic priorities for advancing its antibody-based oncology portfolio and technology platforms.
Investors and observers who follow MGNX news can use this page to review how MacroGenics reports progress in its clinical trials, describes its collaborations and outlines its financial position in official communications. Bookmarking the news feed provides a centralized view of press releases and related information that the company files or references in its SEC disclosures.
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company specializing in antibody-based cancer therapies, has announced its participation in the H.C. Wainwright Global Investment Conference. The event will take place on May 25, 2022, in Miami, FL, where President & CEO Scott Koenig will provide a corporate overview at 11:30 am ET. The company will also conduct one-on-one meetings with investors. A webcast of the presentation will be available on MacroGenics' Investor Relations website for 30 days following the event.
MacroGenics (NASDAQ: MGNX) reported Q1 2022 results, revealing a net loss of $66.4 million, up from $51.3 million in Q1 2021. Revenue declined to $11.1 million from $16.9 million year-over-year. The company is preparing to start a Phase 2/3 prostate cancer study with MGC018 by the end of 2022 and has initiated a Phase 1 study of MGC018 in combination with lorigerlimab for advanced solid tumors. Cash reserves fell to $184 million from $243.6 million, with guidance indicating sufficient funds through 2023 for ongoing projects.
MacroGenics, Inc. (Nasdaq: MGNX) will release its first-quarter 2022 financial results after market close on May 3, 2022. The company will also host a conference call at 4:30 PM ET that same day to discuss the results and recent corporate developments. Interested parties can access the call by dialing (877) 303-6253 for domestic calls or (973) 409-9610 for international calls, using Conference ID# 6791448. A webcast will be available in the Investor Relations section of their website, with a replay accessible for 30 days post-call.
MacroGenics (Nasdaq: MGNX) announced its participation in two investor conferences in March 2022. The first event is the Cowen 42nd Annual Health Care Conference on March 8, where CEO Scott Koenig will join a panel discussion at 10:30 AM ET. The second is the Barclays Global Healthcare Conference on March 15, featuring a corporate overview at 3:50 PM ET. Both events will include one-on-one meetings and webcasts accessible via MacroGenics' investor relations website, with archived replays available for 30 days.
MacroGenics, Inc. (NASDAQ: MGNX) has promoted Eric Risser to Chief Operating Officer, effective February 22, 2022. Risser has been with the company since 2009, significantly contributing to collaboration partnerships, business development, and program management. He previously served as Senior Vice President and Chief Business Officer. The promotion reflects the company's confidence in his leadership abilities to drive product advancements and shareholder value. MacroGenics focuses on developing innovative antibody-based therapeutics for cancer treatment, leveraging advanced technology platforms.
MacroGenics, Inc. (MGNX) has launched a Phase 1 dose escalation study of MGC018 in combination with lorigerlimab, focusing on B7-H3-directed therapies for treating solid tumors. The company plans to meet the FDA to discuss a registration-directed study for MGC018 in metastatic castration-resistant prostate cancer (mCRPC). Financially, MacroGenics reported $77.4 million in revenue for 2021, a decline from $104.9 million in 2020. The net loss widened to $202.1 million, compared to $129.7 million in the previous year. The company maintains a cash runway through 2023.
MacroGenics, a biopharmaceutical company focused on monoclonal antibody therapeutics for cancer, will release its fourth quarter financial results for 2021 on February 24, 2022, after the market closes. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and corporate progress. Investors can access the call by dialing (877) 303-6253 domestically or (973) 409-9610 internationally, with a Conference ID of 1067087. A webcast will also be available on the company's website.
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focusing on monoclonal antibody-based therapies for cancer, will participate in several upcoming virtual conferences in February 2022. Notable events include:
- Guggenheim Healthcare Talks on February 10, 2022, at 9:00 am ET.
- Citi’s 2022 Virtual Immuno-Oncology Summit on February 17, 2022, at 12:30 pm ET.
- 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:40 am ET.
Archived webcasts will be available on MacroGenics' website.
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company, announced its participation in several healthcare conferences in November and December 2021. Key events include:
- Credit Suisse 30th Annual Healthcare Conference: November 9, 2021, at 8:00 am ET.
- Stifel 2021 Virtual Healthcare Conference: November 16, 2021, at 8:00 am ET.
- Evercore ISI HealthCONx Virtual Conference: December 2, 2021, at 8:25 am ET.
- JMP Securities Hematology and Oncology Summit: December 6, 2021, at 1:00 pm ET.
Webcasts of these presentations will be available on their website.
MacroGenics, Inc. (NASDAQ: MGNX) has submitted an IND application for MGD024, a bispecific DART molecule targeting CD123 and CD3 for AML. The FDA approved its GMP manufacturing facility for MARGENZA drug substance. However, enrollment for Cohort A of the Phase 2/3 MAHOGANY study of margetuximab is being discontinued. Financial results for Q3 2021 revealed total revenue of $15.7 million, down from $18.3 million in Q3 2020. R&D expenses rose to $49.8 million, leading to a net loss of $52.9 million. The company expects its cash position to fund operations through 2023.